



Vaccine Candidate against SARS-CoV-2

Guest Editors:

Prof. Dr. Antonella Caputo

Department of Chemical,
Pharmacological and Agricultural
Sciences, University of Ferrara,
44121 Ferrara, Italy

Dr. Francesco Nicoli

Department of Chemical,
Pharmaceutical and Agricultural
Sciences, University of Ferrara,
44123 Ferrara, Italy

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

The quest for a vaccine against SARS-CoV-2 has mobilized a multitude of researchers worldwide that combined their expertise and effort for the rapid development of effective products. In this special issues, we want to highlight:

- the vaccine platforms already available before the COVID-19 pandemic, which have been quickly scaled-up to develop vaccines against SARS-CoV-2
- aspects related to the immunogenicity, safety and efficacy of licensed vaccines, including the durability of immune responses and the protection against variants
- new generations of vaccines/new vaccine candidates against COVID-19
- strategies to improve the efficacy of COVID-19 vaccination
- vaccination strategies for particular populations (e.g. children, the elderly, fragile subjects)
- immunological correlate of protection

Original research articles and short communications on pre-clinical and clinical studies are welcome, as well as reviews and commentaries.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com